Research programme: T-cell receptor therapies - Rebirthel
Alternative Names: TIL-TCRLatest Information Update: 31 Mar 2025
At a glance
- Originator Rebirthel
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours